Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
Parkinson Disease, Idiopathic Parkinson Disease
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
This is a study of the efficacy and safety of preladenant in adult participants with moderate to severe Parkinson's Disease (PD).
- Conditions
- Parkinson Disease, Idiopathic Parkinson Disease, Idiopathic Parkinson's Disease
- Trial name
- NCT01227265
- Testing
- Preladenant
- Volunteers
- 476 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients
This is a prospective study in a cohort of about 30 patients with Idiopathic Parkinson's disease, who will be evaluated with a clinical assessment and an oculometric examination during a time period with specific intervals.
- Trial name
- NCT05795023
- Testing
- NeuraLight
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- NeuraLight
Major Depressive Disorder, Idiopathic Parkinson Disease
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.
- Trial name
- NCT00437125
- Testing
- Duloxetine hydrochloride
- Where
- 13 sites in Italy
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Parkinson's Disease
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.
- Trial name
- NCT00601978
- Testing
- carbidopa/levodopa, Carbidopa/Levodopa/Entacapone
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
- Trial name
- NCT00163085
- Testing
- NR2B NMDA Antagonist CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
Idiopathic Parkinson Disease
Adhesion and Safety of Rotigexole Compared to Neupro®
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the…
- Trial name
- START (NCT07015346)
- Testing
- Rotigexole 8 mg, Neupro ® 8 mg
- Volunteers
- 40 people
- Sponsor
- Eva Pharma
Idiopathic Parkinson Disease
A Study to Evaluate in Patients With Parkinsonian Type Disorders
A Phase 2 study to evaluate the safety, tolerability and initial efficacy of pramipexole ER, given with aprepitant in patients with parkinsonian type disorders
- Trial name
- NCT03683225
- Testing
- CTC-413
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Chase Therapeutics Corporation
Parkinson's Disease, Idiopathic
Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata Husk
The purpose of this trial is to study the effect of the association levodopa/carbidopa with plantago ovata husk in Parkinson´s disease patients of recent diagnostic, that are being treated with levodopa/carbidopa.
- Trial name
- NCT00507715
- Testing
- Plantago ovata husk, hemicellulose crystalline
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Rottapharm Spain
Parkinson
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela \& Cª, S.A.
- Trial name
- EPSILON (NCT04978597)
- Testing
- Opicapone 50 mg
- Where
- Bulgaria
- Volunteers
- 410 people
- Sponsor
- Bial - Portela C S.A.
Idiopathic Parkinson's Disease
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home…
- Trial name
- CARE-ACT (NCT01330290)
- Testing
- Neupro®
- Where
- 54 sites in Germany
- Volunteers
- 148 people
- Sponsor
- UCB Pharma
Idiopathic Parkinson's Disease
Vercise Implantable Stimulator for Treating Parkinson's Disease
The purpose of this study is to document patient outcomes, including effectiveness, safety, and health economic data, for the Boston Scientific implantable deep brain stimulation (DBS) Vercise™ system for bilateral stimulation of…
- Trial name
- VANTAGE (NCT01221948)
- Testing
- Deep Brain Stimulation
- Where
- 7 sites in Austria, France and 4 more
- Volunteers
- 53 people
- Sponsor
- Boston Scientific Corporation
Idiopathic Parkinson Disease
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
This is a study with two sequential cohorts, each with three treatment periods. Single doses of PF-06649751 will be tested in this study, starting at a low dose and escalating to a dose projected to be under the current limits…
- Trial name
- NCT02373072
- Testing
- PF-06649751, Trimethobenzamide Hydrochloride
- Where
- 8 sites in United States, Belgium
- Volunteers
- 18 people
- Sponsor
- Pfizer
Parkinson Disease, Idiopathic
An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease
This clinical study is designed to explore the safety and tolerability of UX-DA001. It will also explore if UX-DA001 works to improve motor function in subjects with Parkinson's disease.
- Trial name
- NCT06778265
- Testing
- UX-DA001
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai UniXell Biotechnology Co., Ltd
Parkinson's Disease
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD…
- Trial name
- NCT01772693
- Testing
- ExAblate Transcranial MRgFUS
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- InSightec
Idiopathic Parkinson's Disease
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
The purpose of this double blind study is to determine whether CERE-120 (adeno-associated virus serotype 2 [AAV2]-neurturin [NTN]) is effective and safe in the treatment of patients with idiopathic Parkinson's Disease.
- Trial name
- NCT00400634
- Testing
- CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
- Where
- 9 sites in United States
- Volunteers
- 58 people
- Sponsor
- Sangamo Therapeutics
Idiopathic Parkinson's Disease
Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists
The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot…
- Trial name
- PIVICOG-PD (NCT01007864)
- Testing
- piribedil, pramipexole or ropinirole
- Where
- 12 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Desitin Arzneimittel GmbH
Idiopathic Parkinson's Disease
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease who are currently being treated with a stable…
- Trial name
- NCT00239564
- Testing
- IPX054 100 mg, IPX054 150 mg, IPX054 200 mg
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Impax Laboratories, LLC
Idiopathic Parkinson´s Disease, Parkinson's Disease
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
- Trial name
- NCT07106021
- Testing
- RNDP-001, Syringe Front-Loading Device
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Kenai Therapeutics
Idiopathic Parkinson Disease
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients
This is a prospective study in a cohort of about 500 patients with Idiopathic Parkinson's disease, examined routinely in the neurological outpatient clinic.
- Trial name
- NCT05437003
- Testing
- NeuraLight software-based platform
- Where
- Israel
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- NeuraLight
Idiopathic Parkinson's Disease
Stalevo in Early Wearing-Off Patients
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian…
- Trial name
- SEWOP (NCT00125567)
- Testing
- Stalevo (levodopa/carbidopa/entacapone), Levodopa/carbidopa
- Where
- 19 sites in Denmark, Finland and 4 more
- Volunteers
- 223 people
- Sponsor
- Orion Corporation, Orion Pharma